User:Mr. Ibrahem/Idursulfase
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Monograph |
| License data | |
| Drug class | Enzyme[1] |
  (what is this?) (verify) | |
Idursulfase, sold under the brand name Elaprase, is a medication used to treat mucopolysaccharidosis II (MPS-II, Hunter syndrome).[1] It is given by gradual injection into a vein.[1] It is used long term.[3] Effects on life expectancy and quality of life is unclear.[4]
Common side effects include rash, fever, headache, high blood pressure, and flushing.[2] Other side effects may include shortness of breath, heartburn, chest pain, and anaphylaxis.[2] It is a form of lysosomal enzyme known as iduronate-2-sulfatase and is made by recombinant DNA technology.[1]
Idursulfase was approved for medical use in the United States in 2006 and Europe in 2007.[1][2] In the United States it costs about 475,000 USD to treat a 35 kg person for a year.[5] In the United Kingdom this amount costs £310,000.[3]
References[edit]
- ^ a b c d e f g "Idursulfase Monograph for Professionals". Drugs.com. Archived from the original on 2 December 2021. Retrieved 25 November 2021.
- ^ a b c d "Elaprase". Archived from the original on 11 December 2021. Retrieved 25 November 2021.
- ^ a b c BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1116. ISBN 978-0857114105.
- ^ "Idursulfase" (PDF). September 2009. Archived (PDF) from the original on 15 April 2021. Retrieved 25 November 2021.
- ^ "Idursulfase Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 25 November 2021.